**Table E4. Data abstraction of randomized controlled trials of NSAIDs**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Country Number of Centers and Setting** | **Inclusion Criteria** | **Number Randomized, Analyzed Attrition** | **Intervention** | **Study Participants** | **Duration of Pain (acute, subacute, chronic)** |
| Herrmann, 2009 | Germany  Multicenter  Outpatient | 18-70 years, sciatica or  lumbosciatica with onset within the last 72 hours with any previous attacks had to be resolved at least 3 months earlier. | Randomized: 171  Analyzed: 171  Attrition: 0 | A: Lornoxicam 8mg tablets,  with 16 mg loading dose on day 1, then 8mg after 8 hours; 8 mg twice per day on days 2-4; 8 mg on day 5  B: Diclofenac: 50 mg twice per day on days 1 and 5;  50mg three times per day on days 2-4.  C: Placebo capsules in lornoxicam  or diclofenac blister packs  Day 5 treatment was optional | Mean age: 51.8 vs. 48.9 vs.  48.4  Gender, male: 56% vs.  53% vs. 58%  Race, Caucasian: 91% vs.  93% vs. 98%  Pain etiology: Sciatica or lumbosciatica | Acute pain, total  duration of previous  low back pain: 53.8 vs.  44.1 vs. 53.9 months |
| Majchrzycki, 2014 | Poland  Single center  Outpatient clinic | 40-60 years old, Pain  lasting longer than 7 weeks, VAS1 and VAS2 scores ≥  25mm of 100mm, no  NSAID or strong analgesic therapy during the last 3 months | Randomized: 59  Analyzed: 54  Attrition: 5 | A. Deep tissue massage +  NSAID (n=26)  B. Deep tissue massage  (n=28) | Mean age: 50.8 vs. 52.6  Gender, female: 13/26 vs.  13/28  Race: NR  Chronic pain: 100% Baseline pain: NR Baseline function: NR QOL: NR | Subacute duration,  weeks: 11.9±3.9 vs.  10.8±2.4 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Duration of**  **Followup** | **Results** | **Adverse Events**  **Including Withdrawals** | **Funding**  **Source** | **Quality** |
| Herrmann, 2009 | 5 days | A vs. B vs. C  Pain intensity difference, mm:  3 hours: -21.0 vs. -18.7 vs. -15.3, p ≤0.05 for A vs. C  4 hours: -22.0 vs. -21.5 vs. -14.8, p ≤0.05 for A vs. C  6 hours: -20.5 vs. -22.4 vs. -14.9, p ≤0.05 for A vs. C  8 hours: -22.0 vs. -24.1 vs. -13.7, p ≤0.05 for A vs. C  Sum of time-weighted pain intensity difference, mm x minute:  0-4 hours: -4020 vs. -3879 vs. -2901, p ≤0.05 for A vs. C  0-6 hours: -6486 vs. -6358 vs. -4713, p ≤0.05 for A vs. C  0-8 hours: -9125 vs. -8833 vs. -6257, p ≤0.05 for A vs. C  Pain Relief (mm):  3 hours: 30.1 vs. 30.8 vs. 26.6  4 hours: 31.7 vs. 33.9 vs. 26.6  6 hours: 31.1 vs. 34.3 vs. 26.1  8 hours: 31.9 vs. 35.6 vs. 23.9, p ≤0.05 for A vs. C  Peak pain intensity difference, A vs. C: -27.9 mm vs. -19.9 mm, p=0.01  Time to peak pain intensity difference, A vs. C: 243 vs. 240 minutes, no difference  Peak pain relief, A vs. C : 38.0 mm vs. 31.1 mm, p=0.05  Time to peak pain relief: no difference Start of peak pain relief: no difference End of peak pain relief: no difference  Duration of peak pain relief: no difference | A vs. B vs. C  Withdrawals: 4 vs. 2 vs. 1  Withdrawals due to AEs: 2 vs. 1 vs. 0  Serious AEs: 0 vs. 2 vs. 0  Nonserious AEs: 11 vs. 7 vs. 7 | Nycomed  Pharma Austria, Merckle GmbH Ulm, Germany | Fair |
| Majchrzycki, 2014 | 2 weeks | Difference scores, no significantly different results between groups on:  Roland-Morris questionnaire: 21.2 vs. 16.1  Oswestry disability index: 24.7 vs. 19.6  VAS1: pain intensity during resting: 16.5 vs. 13.9  VAS2: pain intensity during motion: 3.2 vs. 3.4  VAS3: pain intensity during mobility of the aching area of the spine: 4.8 vs. 8.2 | Withdrawals: 3 vs. 2  Withdrawals due to AEs: NR  Serious AEs: NR Nonserious AEs: NR | Not reported | Fair |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Country Number of Centers and Setting** | **Inclusion Criteria** | **Number Randomized, Analyzed Attrition** | **Intervention** | **Study Participants** | **Duration of Pain (acute, subacute, chronic)** |
| Shirado, 2010 | Japan  Multicenter Orthopedic surgeon clinics | Age 20-64, nonspecific  chronic low back pain of more than 3 months duration | Randomized: 201  Analyzed: 193  Attrition: 8 | A: NSAIDs: loxoprofen  sodium, 60 mg tablet 3 times daily; diclofenac sodium, 25 mg tablet 3 times daily; or zaltoprofen, 80 mg tablet 3 times daily  B: Exercise: medical professionals at each clinic gave instruction of the exercise. 2 types of exercise: trunk strengthening and stretching. 2 sets of 10 repetitions of each exercise per day were encouraged. | Mean Age: 42.5 vs. 42.0  Female: 59% vs. 52% Race: NR  Pain type: All chronic pain  Baseline pain:  VAS (0-10): 3.8 vs. 3.5  QOL scores:  RDQ (0-24): 3.7 vs. 3.0  JLEQ score (0-120): 21.8 vs. 20.5 | ≥ Subacute duration,  details not reported |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Duration of**  **Followup** | **Results** | **Adverse Events**  **Including Withdrawals** | **Funding**  **Source** | **Quality** |
| Shirado, 2010 | 12 months | Baseline to 8 week change ratio:  Pain: VAS: -0.35 vs. -0.44, p=0.332  Function: Finger-floor distance: 0.00 vs. -0.09, p=0.112  RDQ: -0.47 vs. -0.72, p=0.023  JLEQ: -0.44 vs. -0.58, p=0.021 | NR | No commercial  sponsor | Good |

**Please see Appendix C. Included Studies for full study references.**